Article thumbnail

Detection of cancer cells in the cerebrospinal fluid: current methods and future directions

By Cody L Weston, Michael J Glantz and James R Connor


The spread of cancer into the central nervous system is a serious problem leading to neurological symptoms and rapid mortality. The current tools available for detecting the spread of cancer into the cerebrospinal fluid (CSF) are cytology, neurologic examination, and neuroimaging. All three of these methods can be applied in concert to reach a diagnosis, but they all suffer from a lack of sensitivity, leading to delays in treatment in many cases. An overview of research tools in the field of CSF cancer detection reveals a variety of promising technologies that can be used to answer questions about the biology of metastatic cancer and to develop more powerful clinical detection methods. Methods currently under investigation include new immunocytochemistry methods and flow cytometry for the in vitro detection of cells. Additionally, polymerase chain reaction, fluorescence in situ hybridization, capillary electrophoresis with laser-induced fluorescence, and mass spectrometry using matrix-assisted laser absorption-deionization time-of-flight and surface-enhanced laser desorption/ionization time-of-flight techniques are being tested for in vitro assessment of the non-cellular biomarkers in CSF. For in vivo detection of cancer in the CSF, research techniques include certain quantum dot platforms as well as magnetic iron oxide nanoparticles. As systemic therapies for cancer improve, the CNS is becoming a more common site of disease recurrence. This increases the importance of effective detection methods in the CSF, since early intervention can maximize therapeutic benefit. Furthermore, many cell-based detection methods can be combined with therapeutic agents to serve multiple medical functions through a common targeting system

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). 1 H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology
  2. (2005). Abrey LE: Leptomeningeal metastases from leukemias and lymphomas. Cancer Treat Res
  3. (1997). al Saati T: Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications.
  4. (2005). Automated cerebrospinal fluid cytology: limitations and reasonable applications. Anal Quant Cytol Histol
  5. (2010). Bigner DD: Affinitymatured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
  6. (2010). Biocompatible Magnetofluorescent Probes: Luminescent Silicon Quantum Dots Coupled with Superparamagnetic Iron(III) Oxide. ACS Nano
  7. (2010). Bioconjugated quantum dots for cancer research: Present status, prospects and remaining issues. Biotechnol Adv
  8. (2006). Brat DJ: Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics
  9. (2003). Bruchez MP: Immunofluorescent labeling of cancer marker
  10. (2010). C: DNA-bridged bioconjugation of fluorescent quantum dots for highly sensitive microfluidic protein chips. Chem Commun (Camb)
  11. (2003). Causse E, Couderc F: Analysis of tryptophan and tyrosine in cerebrospinal fluid by capillary electrophoresis and “ball lens” UV-pulsed laser-induced fluorescence detection. J Chromatogr A
  12. (2005). Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc)
  13. (2010). Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr Opin Oncol
  14. (2010). Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat
  15. (2004). Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics
  16. (1995). Couderc F: Child cerebrospinal fluid analysis by capillary electrophoresis and laserinduced fluorescence detection. J Chromatogr A
  17. (2007). CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res
  18. (1994). CW: A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid.
  19. (2007). DC: Differential protein expression in male and female
  20. (2010). Deangelis L: Leptomeningeal metastasis in the MRI Era. Neurology
  21. (1997). Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett
  22. (2008). DM: Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy.
  23. (2006). Duhrsen U: Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. Clin Lab Haem
  24. (1994). Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res
  25. (2010). El-Deiry WS: Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep
  26. (2002). Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence.
  27. (1999). Establishment and characterization of a human neuroectodermal cell line (TB) from a cerebrospinal fluid specimen. Brain Res
  28. (2008). Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics.
  29. (2004). Fauck R: Cytodiagnosis of neoplasms of the central nervous system in cerebrospinal fluid samples with an application of selective immunostains in differentiation. Cytopathology
  30. (1999). GY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res
  31. (1999). Heideman RL: Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors.
  32. (2003). Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement. J Pediatr Hematol Oncol
  33. (1980). JB: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol
  34. (2010). JM: Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era.
  35. (1992). JM: Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology
  36. (2009). JR: A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology
  37. (2002). Jr: Boosted decision tree analysis of surfaceenhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem
  38. (2002). LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet
  39. (2010). Lam PYP: Isolation of peptide ligands that interact specifically with human glioma cells. Peptides
  40. (2005). Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res
  41. (1995). LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol
  42. (2004). Macfelda K: MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging
  43. (2010). MD: Biology and therapy of neoplastic meningitis. Curr Oncol Rep
  44. (2007). Meir EG: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.
  45. (2008). Monoclonal antibody therapy for B-cell nonHodgkin’s lymphoma.
  46. (2010). Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol
  47. (2008). Nann T: Quantum dots versus organic dyes as fluorescent labels. Nat Methods
  48. (1996). NB: A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer
  49. (2008). Neoplastic Meningitis. The Oncologist
  50. (2009). NHL SGftSoCDi: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry.
  51. (2001). O’Day SJ: Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients.
  52. (2007). Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics
  53. (2010). Peptide-based probes for targeted molecular imaging. Biochemistry
  54. (1998). Perides G: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer
  55. (2005). Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res
  56. (2003). Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem
  57. (1998). Radioisotope CSF flow studies in leptomeningeal metastases.
  58. (1997). Ramaekers FC, Twijnstra A: Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization.
  59. (1998). Recht LD: Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer
  60. (2007). Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem
  61. (2009). Roncella S: Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis.
  62. (2009). Rugo HS: New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol
  63. (2009). Salmaggi A: Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med
  64. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res
  65. (2002). Serum proteomic patterns for detection of prostate cancer.
  66. (1978). Serum-CSF protein gradients, the blood-GSF barrier and the local immune response.
  67. (2004). Single-cell PCR analysis of the immunoglobulin heavychain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins.
  68. (2004). SJ: Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance.
  69. (2008). Strik H: Automated cerebrospinal fluid cytology. Anal Quant Cytol Histol
  70. (2010). Superparamagnetic Nanospheres for Drug Storage, Targeting, and Imaging: A multifunctional nanocarrier system for cancer diagnosis and treatment.
  71. (1986). The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid.
  72. (2006). The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem
  73. (2010). The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials
  74. (2010). UJ: Quantum dots as contrast agents for in vivo tumor imaging: progress and issues. Anal Bioanal Chem
  75. (1984). Use of monoclonal antibody panel to identify malignant cells in cerebrospinal fluid. Lancet
  76. (1999). Vecht CJ: The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.
  77. (2005). Verbeek MM, Luider TM, Smitt PAS: MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics
  78. (2010). WH: Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment. YSONC
  79. (2005). WH: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood
  80. (2006). X: Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn